Treatment options for patients with triple-negative breast cancer.

Treatment options for patients with triple-negative breast cancer.
复制标题

DOI:
10.1186/1756-8722-3-42
复制
发表时间:
2010-10-27
影响因子:
28.5
通讯作者:
Perez EA
Perez EA
中科院分区:
医学1区
文献类型:
--
作者:
Santana-Davila R;Perez EA

文献摘要

参考文献

被引文献

相似文献

乳腺癌是一种由不同亚型组成的异质性疾病,具有不同的临床病理特征、预后和治疗反应。在过去的十年中,在治疗对激素治疗敏感的乳腺癌以及恶性细胞过度表达或扩增HER2的患者方面取得了重大进展。相比之下,主要由于缺乏分子靶点,三阴性乳腺癌患者的治疗进展甚微。最近对三阴性乳腺癌的自然史、病理生理学和分子特征的了解有所提高,为女性患者的管理和治疗策略提供了新的见解。正在进行的和计划中的转化临床试验可能会优化和改善患有这种疾病的妇女的治疗。
Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as well as in patients whose malignant cells overexpress or amplify HER2. In contrast, mainly due to the lack of molecular targets, little progress has been made in the treatment of patients with triple-negative breast cancer. Recent improved understanding of the natural history, pathophysiology, and molecular features of triple-negative breast cancers have provided new insights into management and therapeutic strategies for women affected with this entity. Ongoing and planned translational clinical trials are likely to optimize and improve treatment of women with this disease.
DOI: 10.1200/jco.2007.14.5375
发表时间: 2008-04-10
影响因子: 45.3
作者:
Burstein, Harold J.;Elias, Anthony D.;Miller, Kathy D.
通讯作者: Miller, Kathy D.
DOI: 10.1093/jnci/92.7.564
发表时间: 2000-04-05
影响因子: 10.3
作者:
Esteller, M;Silva, JM;Herman, JG
通讯作者: Herman, JG
DOI: 10.1017/s146239940500904x
发表时间: 2005-03-30
影响因子: 6.2
作者:
Curtin, Nicola J.
通讯作者: Curtin, Nicola J.
DOI: 10.1158/1078-0432.ccr-06-1109
发表时间: 2007-04-15
影响因子: 11.5
作者:
Carey, Lisa A.;Dees, E. Claire;Perou, Charles M.
通讯作者: Perou, Charles M.
DOI: 10.1038/sj.onc.1209415
发表时间: 2006-06-01
期刊: ONCOGENE
影响因子: 8
作者:
Doane, A. S.;Danso, M.;Gerald, W. L.
通讯作者: Gerald, W. L.